Physician profile
Amy Jasani
NPI 1275973513
$2,224.89
in general payments reported to CMS, 2019-2025
20 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $84.20 · 2021: $229 · 2022: $339 · 2023: $372 · 2024: $274 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $313.98 | 2023-2024 | Tyrvaya |
| Coopervision INC. | $287.83 | 2019-2025 | Myday Contact Lens |
| Alcon Vision LLC | $251.39 | 2019-2025 | Dailies Total1, Dailies, Precision 1 |
| Allergan, INC. | $180.56 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $177.92 | 2019-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $156.09 | 2019-2025 | Acuvue |
| Tarsus Pharmaceuticals, INC. | $140.76 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $116.24 | 2019-2022 | |
| Abbvie INC. | $111.83 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $103.65 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $91.75 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $61.58 | 2021-2022 | |
| Glaukos Corporation | $35.36 | 2025 | Photrexa Viscous and Photrexa |
| Bausch & Lomb Americas INC. | $34.11 | 2023 | Infuse, Vyzulta, Lotemax |
| Johnson & Johnson Surgical Vision, INC. | $33.78 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $32.57 | 2024-2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $29.33 | 2021 | |
| Ocular Therapeutix, INC. | $28.82 | 2020-2024 | Dextenza |
| Thea Pharma INC. | $23.13 | 2023 | |
| Dompe US, INC. | $14.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Jasani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.